

## Updated Proposed Phase 1 and Phase 2 Quality Benchmarks

*December 8, 2023*

**Table 1. Commercial Quality Benchmark Values**

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value
<b>Phase 1 Measures</b>				
Asthma Medication Ratio (Ages 5 – 18)	79%	81%	83%	86%
Asthma Medication Ratio (Ages 19 – 64)	78%	80%	82%	85%
Controlling High Blood Pressure	61%	63%	65%	68%
HbA1c Control for Patients with Diabetes: HbA1c Poor Control <sup>1</sup>	27%	26%	N/A <sup>2</sup>	23%
<b>Phase 2 Measures</b>				
Child and Adolescent Well-Care Visits	N/A	N/A	80%	82%
Follow-up After ED Visit for Mental Illness (7-day)	N/A	N/A	64%	66%
Follow-up After Hospitalization Visit for Mental Illness (7-day)	N/A	N/A	67%	69%

<sup>1</sup> A lower rate indicated better performance.

<sup>2</sup> Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024. OHS will re-evaluate the 2025 Quality Benchmark value after performance is reported for MY 2024 with the potential to adjust the MY 2025 Quality Benchmark value.

**Table 2. Medicaid Quality Benchmark Values**

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value
<b>Phase 1 Measures</b>				
Asthma Medication Ratio (Ages 5 – 18)	66%	68%	70%	73%
Asthma Medication Ratio (Ages 19 – 64)	63%	65%	67%	70%
Controlling High Blood Pressure	61%	63%	65%	68%
HbA1c Control for Patients with Diabetes: HbA1c Poor Control <sup>3</sup>	37%	36%	N/A <sup>4</sup>	33%
<b>Phase 2 Measures</b>				
Child and Adolescent Well-Care Visits	N/A	N/A	66%	68%
Follow-up After ED Visit for Mental Illness (7-day)	N/A	N/A	60%	62%
Follow-up After Hospitalization Visit for Mental Illness (7-day)	N/A	N/A	53%	55%

<sup>3</sup> A lower rate indicates better performance.

<sup>4</sup> Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024. OHS will re-evaluate the 2025 Quality Benchmark value after performance is reported for MY 2024 with the potential to adjust the MY 2025 Quality Benchmark value.

**Table 3. Medicare Advantage Quality Benchmark Values**

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value
<b>Phase 1 Measures</b>				
Controlling High Blood Pressure	73%	75%	77%	80%
HbA1c Control for Patients with Diabetes: HbA1c Poor Control <sup>5</sup>	20%	18%	N/A <sup>6</sup>	15%

**Table 4. Statewide Quality Benchmark Values**

Quality Benchmark Measure	2022 Value	2023 Value	2024 Value	2025 Value
<b>Phase 2 Measures</b>				
Obesity Equity Measure <sup>7,8</sup>	N/A	N/A	1.42	1.38

---

<sup>5</sup> A lower rate indicates better performance.

<sup>6</sup> Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024. OHS will re-evaluate the 2025 Quality Benchmark value after performance is reported for MY 2024 with the potential to adjust the MY 2025 Quality Benchmark value.

<sup>7</sup> This measure is the ratio of statewide obesity rates for Black, non-Hispanic population and White, non-Hispanic population. A rate of 1 indicates that the statewide obesity rates for both populations are identical.

<sup>8</sup> In addition to reporting statewide performance on the Obesity Equity Measure, OHS will also report the three-year rolling average obesity rate for the Black, non-Hispanic population against target values of 37% for 2024 and 35% for 2025.